Updated Jul 16, 2026
PAPADOPOULOS STELIOS has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.62M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | EXEL | EXELIXIS, INC. | A — Grant or award | 8.4K | $0.00 | |
| 2026-04-09 | OVID | Ovid Therapeutics Inc. | A — Grant or award | 17.6K | $2.56 | $45K |
| 2025-06-25 | RGLS | Regulus Therapeutics Inc. | D — Derivative transaction | 64.6K | — | |
| 2025-06-25 | RGLS | Regulus Therapeutics Inc. | J — Other acquisition / disposition | 976.3K | — | |
| 2025-05-29 | EXEL | EXELIXIS, INC. | A — Grant or award | 9.8K | $0.00 | |
| 2025-05-15 | EXEL | EXELIXIS, INC. | S — Open-market sale | 15.9K | $44.35 | $704K |
| 2025-05-15 | EXEL | EXELIXIS, INC. | M — Option exercise | 15.9K | $20.50 | $325K |
| 2025-05-15 | EXEL | EXELIXIS, INC. | S — Open-market sale | 20.6K | $44.35 | $915K |
| 2025-05-15 | EXEL | EXELIXIS, INC. | M — Option exercise | 20.6K | $19.77 | $408K |
| 2025-04-30 | RGLS | Regulus Therapeutics Inc. | A — Grant or award | 62.5K | $0.00 |
PAPADOPOULOS STELIOS is a corporate insider — currently tracked as Director of EXELIXIS, INC. (EXEL). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($1.62M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live PAPADOPOULOS STELIOS profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.